)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Senti Biosciences (SNTI) investor relations material
Senti Biosciences MedInvest Biotech & Pharma Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.MedInvest Biotech & Pharma Conference summary24 Sep, 2025
Scientific and clinical program highlights
Lead program SENTI-202 uses logic-gated gene circuits to enhance selectivity and efficacy in cell therapy for acute myeloid leukemia (AML).
SENTI-202 received orphan drug designation and showed positive preliminary efficacy in an ongoing phase 1 trial, with additional data expected by year-end.
Logic gate technology enables recognition of multiple cancer antigens and spares healthy cells, addressing AML's heterogeneity and lack of clean targets.
SENTI-202 is an off-the-shelf NK cell therapy, engineered with bivalent CARs targeting CD33 and FLT3, and a NOT gate using endomucin to protect healthy hematopoietic stem cells.
Multi-arming with IL-15 enhances NK cell function and persistence, with manufacturing allowing immediate shipment upon patient enrollment.
Clinical trial results and safety
Phase 1 trial enrolled high-risk, relapsed/refractory AML patients, most with multiple prior therapies and poor prognostic indicators.
Safety profile was favorable, with no grade 3 or serious adverse events related to SENTI-202; only mild, manageable reactions observed.
Efficacy data showed complete remission in two of three patients at the recommended phase 2 dose, all with undetectable measurable residual disease.
Overall, 57% of patients achieved complete remission and 100% had MRD-negative responses, with ongoing remissions at data cutoff.
Correlative studies confirmed reduction of leukemic stem cells and preservation of healthy blood cell recovery, supporting the mechanism of action.
Forward-looking statements and next steps
Additional phase 1 data will be presented by the end of the year, targeting a cohort of around 20 patients.
Plans include expanding the pipeline to target solid tumors using similar logic-gated approaches.
Ongoing collaboration with MD Anderson Cancer Center for advanced correlative studies.
Continued optimization of logic gate selection and cell engineering through iterative cell-cell assays.
Explain the NOT logic gate's protective mechanism.
How do SENTI-202 CR rates compare to SOC?
What is the next key milestone for SENTI-202?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Senti Biosciences earnings date
Q3 202513 Nov, 2025
Next Senti Biosciences earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Senti Biosciences Inc. is a biotechnology company engaged in developing innovative cell and gene therapies. The company specializes in the use of gene circuit technologies, which involve designing and programming cells to function as intelligent medicines capable of addressing various diseases. Senti Biosciences’ platform focuses on three main areas: off-the-shelf CAR-NK cells for oncology, gene therapies targeting specific tissues, and cell therapies for regenerative medicine. Their lead product candidates include therapies targeting different types of cancer using CAR-NK cells engineered with these gene circuits. Senti Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage